No Data
Technological breakthroughs and innovation leadership, how LUZHU BIOTECH-B (2480.HK) reshapes the vaccine industry landscape.
In the context of the Global vaccine Industry accelerating technological iteration and market expansion, Chinese Biomedical companies are reshaping the industry landscape through innovative breakthroughs. With the validation of mRNA technology, the acceleration of multi-valent vaccine research and development, and the continuous release of significant products such as the shingles vaccine, the vaccine industry has entered a new stage driven by "independent innovation + globalization." Recently, Luzhu Biomedical released its 2024 annual performance report, showcasing breakthrough progress in its core product LZ901 shingles vaccine, as well as the layout of innovative vaccine pipelines such as HSV-1/HSV-2, demonstrating the technical prowess of Chinese innovative vaccine companies.
[Brokerage Focus] Jianyin International maintains an outperform rating on Greentown Biotech (02480), stating that its full-year performance for 2024 will exceed expectations.
Jinwu Financial News | Jianyin International's Research Reports indicate that for Greentube Biotech (02480), the performance in the second half of 2024 and for the entire year of 2024 exceeds expectations, with a net loss improving compared to the previous year. Excluding one-off items, the bank's adjusted net loss estimates for the second half of 2024 and for the entire year of 2024 are 0.167 billion yuan and 58 million yuan, respectively, better than their previous estimates of 0.282 billion yuan and 0.173 billion yuan loss, and compared to the losses of 0.223 billion yuan and 0.17 billion yuan in the second half of 2023 and for the entire year of 2023, the situation is not as severe.
Luzhu Biotechnology's Attributable Loss Narrows in 2024
Green Bamboo Biotechnology announced the annual results for 2024. The listing application for the core product LZ901 in China has been accepted, accelerating the commercialization process.
HONG KONG, March 19, 2025 /PRNewswire/ -- The Board of Directors of Peking Green Bamboo Biotechnology Co., Ltd. ("Green Bamboo Biotechnology" or "the Company") is pleased to announce the audited consolidated annual results of the Company and its subsidiaries (collectively referred to as "the Group") for the year ended December 31, 2024 ("the Reporting Period"), along with the comparative figures for the year ended December 31, 2023. Since its establishment in 2001, Green Bamboo Biotechnology has been focused on the field of human medicine and has built a technology platform based on its understanding of immunology and protein engineering, enabling the Group to develop products that are efficient, high purity, and stable.
LUZHU BIOTECH-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024
LUZHU BIOTECH-B (02480.HK) will hold a Board of Directors meeting on March 18 to consider and approve the annual performance.
Gelonghui on March 6 announced that LUZHU BIOTECH-B (02480.HK) will hold a Board of Directors meeting on March 18, 2025 (Tuesday) to consider and approve the group's annual performance for the year ending December 31, 2024, and to discuss the proposal for a final dividend distribution (if any).
